TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8054915

Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2a at a dose of 1 x 10(6) units/day sc for 28 days with CYA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2a at a dose of 3 x 10(6) units/day sc for 28 days with CYA
Number of subjects: 22

Group type: COMPARATOR
Intervention: CYA alone
Number of subjects: 22
Study: 3281186

Group type: EXPERIMENTAL
Intervention: Pelvic and para-aortic irradiation
Number of subjects: 441

Group type: COMPARATOR
Intervention: Pelvic irradiation alone
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Para-aortic irradiation
Number of subjects: 441
Study: 31434138

Group type: EXPERIMENTAL
Intervention: Chronic strength training with front-step exercise using a conical pulley, 2-3 sets of 6 repetitions each leg, during 9 weeks (CPG, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG, n=10)
Number of subjects: 20
Study: 28754796

Group type: EXPERIMENTAL
Intervention: PCPT placebo arm
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: PCPT finasteride arm
Number of subjects: 292
Study: 25910923

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: ART-Immediate (ART-Immed)
Number of subjects: 564

Group type: COMPARATOR
Intervention: ART-Deferred (ART-Def)
Number of subjects: 564
Study: 22588852

Group type: EXPERIMENTAL
Intervention: Methylprednisolone with imipenem
Number of subjects: 29

Group type: COMPARATOR
Intervention: Imipenem alone (Control)
Number of subjects: 29
Study: 21414969

Group type: EXPERIMENTAL
Intervention: Self-management support (SMS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-self-management support (non-SMS)
Number of subjects: 54
Study: 19515371

Group type: COMPARATOR
Intervention: Drug conservation (DC)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Viral suppression (VS)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Total HDL-p
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Large HDL-p
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Small HDL-p
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: VLDL-p
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: LDL-p
Number of subjects: 728
Study: 16453980

Group type: EXPERIMENTAL
Intervention: Napping
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Napping plus caffeine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Napping plus caffeine (Field Study)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (Field Study)
Number of subjects: 121
Study: 15022022

Group type: EXPERIMENTAL
Intervention: Thighs-flat position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional lithotomy position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lumbar pad insertion
Number of subjects: 20
Study: 11704584

Group type: EXPERIMENTAL
Intervention: 100 microg budesonide
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: 100 microg budesonide plus 4.5 microg formoterol
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide plus 4.5 microg formoterol
Number of subjects: 1970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1970

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide
Number of subjects: 1970
Study: 9347001

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no NO)
Number of subjects: 49
Study: 7643587

Group type: EXPERIMENTAL
Intervention: Additional physical education (1 hour per day throughout primary schooling)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control class-cohorts (preceding and succeeding classes)
Number of subjects: 546
Study: 3038036

Group type: EXPERIMENTAL
Intervention: High fibre diet low in vasoactive amines
Number of subjects: 39

Group type: COMPARATOR
Intervention: High fibre diet alone
Number of subjects: 39
Study: 31882530

Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 1105
Study: 30125287

Group type: EXPERIMENTAL
Intervention: Post-encoding emotion (neutral, positive, or negative video)
Number of subjects: 0
Study: 27027634

Group type: EXPERIMENTAL
Intervention: 6 mg/kg grapiprant suspension
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg/kg grapiprant suspension
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6 mg/kg grapiprant tablet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg/kg grapiprant tablet
Number of subjects: 16
Study: 25017614

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lovastatin and Placebo
Number of subjects: 0
Study: 22399767

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over the occipital cortex in the WM condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over the occipital cortex in the priming condition
Number of subjects: 0
Study: 20100281

Group type: EXPERIMENTAL
Intervention: Ghrelin (15 pmol kg(‐1) min(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 19102593

Group type: EXPERIMENTAL
Intervention: Threat cue (aversive white noise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cue (neutral cue)
Number of subjects: 0
Study: 16106334

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT) for 8 sessions over 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 11828293

Group type: EXPERIMENTAL
Intervention: Vancomycin (1 g every 12 hours)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Cefazolin (1 g every 8 hours)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 885

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 885
Study: 9895384

Group type: COMPARATOR
Intervention: Low dose amino acids (LDA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High dose amino acids (HDA)
Number of subjects: 8
Study: 7568441

Group type: EXPERIMENTAL
Intervention: Low-protein drink preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-protein drink preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-protein lunch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-protein lunch
Number of subjects: 0
Study: 2127017

Group type: EXPERIMENTAL
Intervention: External CO2 loading with controlled variations of inspiratory gas compositions aimed at a constant PetCO2 of 6.5 kPa (49 mm Hg) during moderate exercise.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate exercise without external CO2 loading.
Number of subjects: 0
Study: 153863

Group type: EXPERIMENTAL
Intervention: 75 mg/day of Ro 10‐9359
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg twice every week of Ro 10‐9359
Number of subjects: 30
Study: 31377456

Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31553835

Group type: EXPERIMENTAL
Intervention: Quintupling the dose of fluticasone (to 250 μg twice a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doubling the fluticasone (to 100 μg twice a day) and adding salmeterol (50 μg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol (low-dose fluticasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol (medium-dose fluticasone)
Number of subjects: 0
Study: 27858210

Group type: EXPERIMENTAL
Intervention: Ring-shaped thread counter traction ESD (RE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional ESD (CE)
Number of subjects: 45
Study: 26945216

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) with standard care
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Interferential Therapy (IFT) with standard care
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 105
Study: 24818541

Group type: EXPERIMENTAL
Intervention: Dry-land strength group (LSG)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In-water strength group (WSG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 19
Study: 22308084

Group type: EXPERIMENTAL
Intervention: Concordant LV leads (n=61)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Long RV-LVs (≥82 ms)
Number of subjects: 85

Group type: COMPARATOR
Intervention: RV lead positions (RV apex n=43, RV high posterior septum n=42)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Independent predictors for reverse remodeling
Number of subjects: 85
Study: 20697200

Group type: EXPERIMENTAL
Intervention: Hib(2.5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hib(5 µg)‐MenC(10 µg)‐MenY(10 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hib(5 µg)‐MenC(5 µg)‐MenY(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hib(5 µg)‐MenC(5 µg)‐TT co-administered with DTPa‐HBV‐IPV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed conjugate MenC‐CRM197 vaccine co-administered with DTPa‐HBV‐IPV/Hib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HibMenCY and HibMenC conjugate vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HibMenCY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 0
Study: 18374301

Group type: EXPERIMENTAL
Intervention: 1% azithromycin in DuraSite
Number of subjects: 279

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 279
Study: 15649263

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP, 200 microg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12420198

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 27
Study: 10612505

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 31
Study: 8546605

Group type: EXPERIMENTAL
Intervention: 750,000U of streptokinase (SK) in 15 min
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1.5 million U of streptokinase (SK) in 30 min
Number of subjects: 110
Study: 1525095

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 444

Group type: COMPARATOR
Intervention: Active policy (immediate oxytocin infusion)
Number of subjects: 444
Study: 3839262

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-prednisone (CP)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, procarbazine and prednisone (COPP)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BCNU, cyclophosphamide, vincristine, and prednisone (BCVP)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Maintenance therapy with periodic BCVP reinduction
Number of subjects: 128
Study: 31155161

Group type: EXPERIMENTAL
Intervention: MOSAIC treatment (two 60-minute home-based sessions and two 20-minute booster telephone calls incorporating behavior-change techniques)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention-control comparison
Number of subjects: 24
Study: 30462654

Group type: EXPERIMENTAL
Intervention: Enhanced surveillance strategies (absenteeism monitoring in schools and cohort families with a toll-free number)
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Age group 0 to 5 years
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Age group 6 to 8 years
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Age group 9 to 15 years
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Living conditions (sharing domestic space with other families)
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Complete protection with screens in doors and windows
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Medium and high risk areas
Number of subjects: 1844
Study: 27103215

Group type: EXPERIMENTAL
Intervention: Dilemma-focused therapy (DFT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Individual manualized CBT
Number of subjects: 128
Study: 24662855

Group type: EXPERIMENTAL
Intervention: TEG-guided dosing (50 mg twice a day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard dosing (30 mg twice a day)
Number of subjects: 87
Study: 23860520

Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen (TAM)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) alone
Number of subjects: 110
Study: 20962021

Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle program of weight management
Number of subjects: 704
Study: 19564296

Group type: EXPERIMENTAL
Intervention: Electronic health record-based clinical alerts for influenza vaccine at intervention sites
Number of subjects: 11919

Group type: COMPARATOR
Intervention: Control sites (no alerts)
Number of subjects: 11919
Study: 17309130

Group type: EXPERIMENTAL
Intervention: sICAM-1 levels in SLE patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: sVCAM-1 levels in SLE patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fasting insulin levels in SLE patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HOMA-IR in SLE patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HOMA beta-cell in SLE patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: sICAM-1 variability in SLE patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: sICAM-1 levels in controls
Number of subjects: 68

Group type: COMPARATOR
Intervention: sVCAM-1 levels in controls
Number of subjects: 68
Study: 15459165

Group type: EXPERIMENTAL
Intervention: Private practitioners
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Public practitioners
Number of subjects: 1101
Study: 11438321

Group type: EXPERIMENTAL
Intervention: 250 microg of recombinant hCG SC
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 500 microg of recombinant hCG SC
Number of subjects: 297

Group type: COMPARATOR
Intervention: 10,000 U USP urinary hCG IM
Number of subjects: 297
Study: 9849035

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 7727578

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zalcitabine (ddC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antiretroviral treatment (No Rx)
Number of subjects: 0
Study: 2035339

Group type: EXPERIMENTAL
Intervention: Combination of medicamentous therapy and percutaneous drainage
Number of subjects: 33

Group type: COMPARATOR
Intervention: Metronidazole and chlorochin
Number of subjects: 33
Study: 6948504

Group type: EXPERIMENTAL
Intervention: Intervention group (smoking cessation and dietary changes)
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1232
Study: 30797542

Group type: EXPERIMENTAL
Intervention: Trochanteric Support Plate (TSP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Trochanteric Support Plate (NoTSP)
Number of subjects: 100
Study: 28704587

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50, 125, 300 or 600 mg weekly
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dutasteride 2.5 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25957330

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (CRT) followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Four cycles of CAPOX followed by CRT and surgery
Number of subjects: 108
Study: 23621902

Group type: EXPERIMENTAL
Intervention: BOC/RGT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOC/PR48
Number of subjects: 0

Group type: COMPARATOR
Intervention: PR48
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOC/PR48 vs BOC/RGT
Number of subjects: 0
Study: 21823273

Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (EA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 Hz electroacupuncture (EA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 Hz electroacupuncture (EA)
Number of subjects: 50
Study: 19478637

Group type: EXPERIMENTAL
Intervention: Protocol B (100 kV(p) and 140 eff mA s)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Protocol C (80 kV(p) and 180 eff mA s)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Protocol A (standard protocol, 120 kV(p) and 100 eff mA s)
Number of subjects: 210
Study: 17968938

Group type: EXPERIMENTAL
Intervention: Quinapril 80 mg/day
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 14988901

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy (IBT)
Number of subjects: 0
Study: 11802510

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g t.d.s. for 4 weeks (SAC group; n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.d. for the first 7 days and 40 mg o.d. for the next 3 weeks (PAC group; n = 60)
Number of subjects: 120
Study: 9919095

Group type: EXPERIMENTAL
Intervention: Preadmission telephone intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8116719

Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Explora
Number of subjects: 248

Group type: COMPARATOR
Intervention: Accurette
Number of subjects: 248
Study: 1685675

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg
Number of subjects: 9
Study: 7449642

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment with prednisolone and azathioprine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no immunosuppressive treatment)
Number of subjects: 9
Study: 31355249

Group type: EXPERIMENTAL
Intervention: Prediction nomogram based on serum long noncoding RNA (lncRNA)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: High expression of lnc-EPS15L1-2:1 in HCC cell lines
Number of subjects: 242
Study: 27588568

Group type: EXPERIMENTAL
Intervention: Liposomal iron 28 mg (LI28)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Liposomal iron 14 mg (LI14)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ferrous iron 30 mg (FI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 80
Study: 26497059

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (Group S)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative methylprednisolone before sevoflurane anesthesia (Group S + MP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous propofol (Group C)
Number of subjects: 90
Study: 24106757

Group type: EXPERIMENTAL
Intervention: 0.05% S. flavescens extract cream
Number of subjects: 0
Study: 22030046

Group type: EXPERIMENTAL
Intervention: Inexpensive-modified transobturator vaginal tape procedure
Number of subjects: 156

Group type: COMPARATOR
Intervention: GYNECARE TVT-O procedure
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 156
Study: 18761603

Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy (n = 59)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination therapy (n = 61)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy with low viraemia (≤300,000 IU/mL)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination therapy with low viraemia (≤300,000 IU/mL)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination therapy with intermediate viraemia (>300,000 IU/mL and ≤700,000 IU/mL)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Peg‐IFN alpha‐2a monotherapy with high viraemia (>700,000 IU/mL)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination therapy with high viraemia (>700,000 IU/mL)
Number of subjects: 144
Study: 17845650

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125% with sufentanil (1 microg/xml)
Number of subjects: 72

Group type: COMPARATOR
Intervention: levobupivacaine 0.0625% with sufentanil (1 microg/xml)
Number of subjects: 72
Study: 15576515

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 11468498

Group type: EXPERIMENTAL
Intervention: Collaborative care program supervised by a psychiatrist and a primary care expert, providing intervention services for 12 months using antidepressant medications and Problem Solving Treatment in Primary Care.
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 1750
Study: 9503770

Group type: EXPERIMENTAL
Intervention: Topical anesthetics (various types including vapocoolants, needleless injection systems, iontophoresis, EMLA Cream)
Number of subjects: 0
Study: 8061739

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (enteral administration of a balanced glucose-electrolyte solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral rehydration solutions with additional benefits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 3361903

Group type: EXPERIMENTAL
Intervention: Alcohol (dose not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public self-awareness (normal vs high)
Number of subjects: 0
Study: 29504427

Group type: EXPERIMENTAL
Intervention: PF‐06438179/GP1111
Number of subjects: 151

Group type: COMPARATOR
Intervention: infliximab‐EU
Number of subjects: 151

Group type: COMPARATOR
Intervention: infliximab‐US
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 151